Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
CPT: Pharmacometrics & Systems Pharmacology|March 21, 2017
Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body WeightM M Hutmacher, K Papp, S Krishnaswami, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 20, 2012
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasisR G Langley, K Papp, A B Gottlieb, et al.
Nature Communications|October 19, 2017
Mitigating oxygen loss to improve the cycling performance of high capacity cation-disordered cathode materialsJinhyuk Lee, Joseph K Papp, Raphaële J Clément, et al.
Teaching and Learning in Medicine|August 22, 2022
A Multi-institutional Study of the Feasibility and Reliability of the Implementation of Constructed Response Exam QuestionsDoreen M Olvet, Jeffrey B Bird, Tracy B Fulton, et al.
Lancet (London, England)|April 22, 2008
Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III studyK Papp, R Bissonnette, L Rosoph, et al.
Teaching and Learning in Medicine|October 19, 2011
Analysis and publication rates of Clerkship Directors in Internal Medicine (CDIM) annual meeting abstracts 1995-2005Klara K Papp, Elizabeth A Baker, Liselotte N Dyrbye, et al.
The Journal of Physical Chemistry Letters|February 28, 2017
Poly(vinylidene fluoride) (PVDF) Binder Degradation in Li-O<sub>2</sub> Batteries: A Consideration for the Characterization of Lithium SuperoxideJoseph K Papp, Jason D Forster, Colin M Burke, et al.
The British Journal of Dermatology|July 17, 2013
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatmentB Strober, M Buonanno, J D Clark, et al.
The British Journal of Dermatology|May 18, 2006
Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trialK Reich, F O Nestle, K Papp, et al.
The British Journal of Dermatology|June 14, 2005
Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trialK Wolff, C Fleming, J Hanifin, et al.
Pageof 12